Market Updates, Products & Ingredients

Immudyne Nutritional Launches ElderPureMune, a Beta-Glucan Elderberry Blend

Immudyne is complementing its flagship PureMune ingredient with BerryShield Elderberry from Denmark’s Asiros Nordic.

...

By: Mike Montemarano

Immudyne Nutritional has partnered with Asiros Nordic to launch ElderPureMune, a gummy supplement which features the former company’s PureMune beta-glucan and BerryShield, an elderberry extract from the latter company.
 
“We’re excited to be able to offer our powerful PureMune beta-glucan ingredient, now combined with Asiros Nordic’s Innovative BerryShield ingredient,” said Mark McLaughlin, chief executive officer of Immudyne Nutritional.
 
While conventional beta-glucan ingredients typically need six to 12 days of supplementation to produce a clinically-relevant response in one immune pathway with a minimum dose of 250 mg, PureMune is evidenced to have onset of action within three hours. It is also linked to three different components of immunity, at an efficacious dose of 30 mg daily.1
 
The ingredient is manufactured in a FDA-registered facility, and its tested by Eurofins Sceintific using carbon-13 high-resolution nuclear magnetic resonance to validate PureMune’s purity, authenticity, and lack of common allergens.
 
Black elderberry produced by Asiros Nordic uses a solvent-free technology that protectively envelops all of the berry’s components that are typically destroyed in conventionally-processed elderberry products.
 
“Our superior-quality famr to finish BerryShield Elderberry is an ideal addition to what is perhaps the world’s finest beta-glucan ingredient, PureMune from Immudyne,” said Jan Kuhlmann, PhD, CEO of Asiros Nordic.
 
 Immudyne and Asiros Nordic have collectively reached an agreement which stipulates that Asiros Nordic will not use any other beta-glucan ingredient and Immudyne will not use any other elderberry ingredient.
 
References
 
1.     Bagatela, B.S. et al. (2023) Effect of Beta-Glucan on the Improvement of Immunity in Healthy Individuals during the Flu Season: A Pilot, Prospective and Open-label Clinical Trial. HealthMED 17 (1)
 

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Related Breaking News